Healthcare

Merck’s Welireg‑Keytruda Combination Gains FDA Approval for Adjuvant Kidney Cancer

The clearance expands Merck’s oncology portfolio into the adjuvant setting, offering a new therapeutic option for patients at risk of disease recurrence and potentially increasing the market size for both drugs beyond their existing advanced‑disease indications.